Velesco Pharma Acquires New R&D and cGMP Analytical Lab
Pharmaceutical Technology's In the Lab eNewsletter
he acquisition expands the company’s formulation and analytical R&D services.
Velesco Pharm, a development and clinical manufacturing company, has acquired a new facility in Wixom, MI, that expands and enhances its formulation and analytical R&D capabilities, the company announced on Oct. 23, 2018.
The acquisition and fit-out of the new facility double the company’s formulation and analytical laboratory space. The increase in capacity expands its research and cGMP services, including formulation development, analytical method development/validation, release and stability testing, and cGMP clinical manufacturing. The move to the expanded facility will occur before the end of 2018.
“Our new laboratory is impressively designed and equipped, and we will be increasing our scientific team such that we can meet our clients’ growing demand for pharmaceutical formulation and analytical services,” said Dave Barnes, PhD, CEO at Velesco, in a company press release.
Source: Velesco Pharm
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
